Breaking News

Financial Report: Amgen

April 23, 2014

Revenues up 7% in the quarter


1Q Revenues: $4.5 billion (+7%)

1Q Earnings: $1.1 billion (-25%)

Comments: Growth in the quarter was driven by newly launched Kyprolis, XGEVA (+25%), Prolia (+38%), and Neulasta sales (+5%). Enbrel sales were down 5% to $924 million and Aranesp sales were down 2% to $177 million, mainly due to lower demand. EPOGEN sales increased 6% to $462 million. Sensipar/Mimpara sales increased 2% to $178 million. Combined sales of Vectibix and Nplate increased 18% to $101 million. R&D expenses were up 17% to $994 million, attributed to the addition of Onyx programs. Earnings were impacted by the end of the ENBREL profit share in 4Q13.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks